Insight Molecular Diagnostics Inc. (IMDX) Stock

About Insight Molecular Diagnostics Inc.

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

Insight Molecular Diagnostics Inc. is led by CEO Joshua Riggs, employs 46 people, headquartered in US, publicly traded since 2015.

Insight Molecular Diagnostics Inc. (IMDX) stock trades at $2.83 with a market capitalization of $92.61M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.94, reflecting a net loss over the last twelve months, a negative price-to-book of -5.08, reflecting negative shareholders' equity, price-to-sales of 57.71. Over the past 52 weeks the stock has ranged between $2.42 and $8.51, and currently trades 66.7% below its 52-week high.

On profitability, Insight Molecular Diagnostics Inc. generates a return on equity (ROE) of 271.76% (not meaningful, as shareholders' equity is negative), return on capital employed of -223.06%, an operating margin of -775.00%, a net profit margin of -24.55%.

Official website: imdxinc.com

Insight Molecular Diagnostics Inc. by the numbers, 2016–2025

Between 2016 and 2025 Insight Molecular Diagnostics Inc. reported revenue of $0 rising to $4.0M. Compounded, revenue has grown 31.9% a year over five years, 58.7% over three, 100.0% over the last twelve months. Net profit fell to $-50.0M.

The most recent net margin is -24.55%. On a trailing twelve-month basis to Jun '26, revenue is $1.0M and net profit $-49.0M.

Borrowings rose from $1.0M to $3.0M, cash on hand is $18.0M, cash from operations was $-22.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 49.7% over five years, and was 161.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Insight Molecular Diagnostics Inc. (IMDX) — frequently asked questions